As Big DX Companies Consolidate, What Are Smaller Companies To Do?
Executive Summary
If large diagnostics companies are consolidating at a record pace these days, smaller companies are also struggling for ways to cope with the brutalities of the current market. Some are cutting back on projects or looking to eliminate altogether their involvement in diagnostics. Others are forging relations with other small companies, something they haven't done much of in the past.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.